AN2 Therapeutics expects three phase 2 readouts next year and has $80 million in cash runway into 2029.
ANTX · AN2 Therapeutics, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 70%
- Last earnings
- May 19, 2026
- Latest filing
- 10-Q · Nov 9
- Price history
- Mar 2022 to Nov 2026
Latest documents
AN2 Therapeutics received FDA clearance for its polycythemia vera trial, plans to dose 10 patients in the sentinel cohort in December and expects milestone updates throughout 2027. The broader trial will enroll 75 patients, with initial data expected around May.
AN2 Therapeutics had $80.2 million in cash and investments, expecting its current operating plan to fund operations for at least 12 months. Phase 2 startup was underway for epetraborole in polycythemia vera, while an investigator-initiated M. abscessus trial enrolled patients.
AN2 Therapeutics said the global Phase 2 study of oral epetraborole for polycythemia vera (PV) was cleared in all planned jurisdictions, with enrollment expected by year-end. Third-quarter net loss was $8.0 million, versus $9.4 million in 2025.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| cash, cash equivalents and investments | $80.2M | as of September 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ANTX
this stock
AN2 Therapeutics, Inc.
|
$192.75M | +345.6% | — | — | 6.4% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 10, 2026
- This year
- 21
AN2 Therapeutics expects three phase 2 readouts next year and has $80 million in cash runway into 2029.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ANTX | +11.7% | +43.1% | +24.8% | +12.1% | +345.6% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +20.2% | +52.3% | +34.0% | +20.9% | +344.5% |